close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Duration of Pain Relief

In order for viscosupplementation to be most effective, your patients must complete their full course of treatment—so fewer injections may mean better compliance.

As you can see from the chart below (based on data from each viscosupplement’s product label), SYNVISC® not only provides unsurpassed pain relief, it also provides a more favorable treatment schedule—just 3 injections for up to 6 months of relief from OA knee pain.

SYNVISC provides up to 6 months of pain relief with fewer injections

Duration of relief indicated in approved labeling

1. Hyalgan [Product Information].New York, NY: Sanofi-Synthelabo, Inc.; 2001.
2 Supartz [Product Information].Memphis, TN: Smith & Nephew, Inc.; 2004.
3. Orthovisc [Product Information].Woburn, MA:Anika Therapeutics, Inc.; 2004.
4. Euflexxa [Product Information]. Suffern, NY: Ferring Pharmaceuticals Inc.; 2005.

Hyalgan is a registered trademark of Fidia S.P.A.
Supartz is a registered trademark of Seikugaku.
Orthovisc is a registered trademark of Anika Therapeutics, Inc.
Euflexxa is a trademark of Ferring Pharmaceuticals Inc.




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)